(Q36244620)

13 August 2017

1 reference

title

Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction (English)

1 reference

13 August 2017

1 reference

Paul D Miller

1

1 reference

13 August 2017

publication date

1 September 2005

1 reference

Current osteoporosis reports

13 August 2017

published in

1 reference

13 August 2017

volume

3

1 reference

13 August 2017

issue

3

1 reference

13 August 2017

page(s)

103-110

1 reference

https://scigraph.springernature.com/pub.10.1007/s11914-005-0018-6

13 August 2017

exact match

0 references

cites work

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

1 reference

12 December 2020

Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography

1 reference

12 December 2020

Study subjects and ordinary patients

1 reference

12 December 2020

Corticosteroid osteoporosis

1 reference

12 December 2020

Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women

1 reference

12 December 2020

The treatment of osteoporosis. Antiresorptive therapy

1 reference

12 December 2020

Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk

1 reference

12 December 2020

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

1 reference

12 December 2020

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis

1 reference

12 December 2020

Surrogates for fracture endpoints in clinical trials

1 reference

12 December 2020

Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients

1 reference

12 December 2020

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

1 reference

12 December 2020

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

1 reference

12 December 2020

Bone matters: are density increases necessary to reduce fracture risk?

1 reference

12 December 2020

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

12 December 2020

Executive summary International Society for Clinical Densitometry position development conference Denver, Colorado July 20-22, 2001.

1 reference

12 December 2020

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

1 reference

12 December 2020

Basic biomechanical measurements of bone: a tutorial

1 reference

12 December 2020

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

1 reference

12 December 2020

Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis

1 reference

12 December 2020

How useful are measures of BMD and bone turnover?

1 reference

12 December 2020

Effects of Intermittent Parathyroid Hormone Administration on Bone Mineralization Density in Iliac Crest Biopsies from Patients with Osteoporosis: A Paired Study before and after Treatment

1 reference

12 December 2020

The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover

1 reference

12 December 2020

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

1 reference

12 December 2020

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

1 reference

12 December 2020

Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids

1 reference

12 December 2020

Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy

1 reference

12 December 2020

Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis

1 reference

12 December 2020

Bisphosphonates: pharmacology, mechanisms of action and clinical uses

1 reference

12 December 2020

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group

1 reference

12 December 2020

Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study

1 reference

12 December 2020

Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy

1 reference

12 December 2020

Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial

1 reference

12 December 2020

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

12 December 2020

Bone material properties and mineral matrix contributions to fracture risk or age in women and men

1 reference

12 December 2020

Effect of glucocorticoids on bone density

1 reference

12 December 2020

Vitamin D3 and calcium to prevent hip fractures in elderly women

1 reference

12 December 2020

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

1 reference

12 December 2020

A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids

1 reference

12 December 2020

Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys

1 reference

12 December 2020

Revival of bone strength: the bottom line

1 reference

12 December 2020

Glucocorticoid-induced osteoporosis: treatment options and guidelines

1 reference

12 December 2020

Constant mineralization density distribution in cancellous human bone

1 reference

12 December 2020

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

1 reference

12 December 2020

Influence of estrogen therapy at conventional and high doses on the degree of mineralization of iliac bone tissue: a quantitative microradiographic analysis in postmenopausal women

1 reference

12 December 2020

Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis

1 reference

12 December 2020

Nonresponders to osteoporosis therapy

1 reference

12 December 2020

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial

1 reference

12 December 2020

Importance of precision in bone density measurements

1 reference

12 December 2020

Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis

1 reference

12 December 2020

Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters

1 reference

12 December 2020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

12 December 2020

Statistical validation of intermediate endpoints for chronic diseases

1 reference

12 December 2020

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

12 December 2020

An update on glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate

1 reference

12 December 2020

Uncertain future of trials in osteoporosis

1 reference

12 December 2020

Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results

1 reference

12 December 2020

Bone fragility and collagen cross-links.

1 reference

12 December 2020

Densitometry in glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis

1 reference

12 December 2020

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

10.1007/S11914-005-0018-6

Identifiers

DOI

1 reference

13 August 2017

1 reference